Optimal drug regimens for primary biliary cirrhosis: A systematic review and network meta-analysis

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24533-24549

  Zhu, Gui Qi ^a,b   Huang, Sha ^a,b   Huang, Gui Qian ^a,b   Wang, Li Ren ^a,b   Lin, Yi Qian ^a,b   Wu, Yi Ming ^a,b   Shi, Ke Qing ^a,b   Wang, Jiang Tao ^a,b   Zhou, Zhi Rui ^c   Braddock, Martin ^d   Chen, Yong Ping ^a,b   Zhou, Meng Tao ^a   Zheng, Ming Hua ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Adverse events; Indirect comparison; Network meta analysis; Primary biliary cirrhosis; UDCA based therapy

Indexed keywords

AZATHIOPRINE; BEZAFIBRATE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; METHOTREXATE; PENICILLAMINE; URSODEOXYCHOLIC ACID; CYCLOSPORIN;

ARTHRALGIA; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG SAFETY; HUMAN; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; MYASTHENIA; OUTCOME ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADULT; AGED; BILE DUCT; COMBINATION DRUG THERAPY; FEMALE; LIVER CIRRHOSIS, BILIARY; MALE; META ANALYSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; AZATHIOPRINE; BEZAFIBRATE; BILE DUCTS; COLCHICINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; METHOTREXATE; MIDDLE AGED; PENICILLAMINE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84943407498     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4528     Document Type: Article

References (73)

1. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Seminars in immunopathology. 2009;31:283-307.
2. Zhu GQ, Shi KQ, Huang S, Huang GQ, Lin YQ, Zhou ZR, Braddock M, Chen YP, Zheng MH. Network metaanalysis of randomized controlled trials:efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine. 2015;94:e609.
3. Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis:tenyear results. Hepatology (Baltimore, Md.). 2004;39:915-923.
4. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al. The Canadian Multicenter Doubleblind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology (Baltimore, Md.). 1994;19:1149-1156.
5. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284-1290.
6. Poupon RE, Poupon R, Balkau B. Ursodiol for the longterm treatment of primary biliary cirrhosis. The UDCAPBC Study Group. The New England journal of medicine. 1994;330:1342-1347.
7. Combes B, Carithers RL, Jr., Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, Munoz SJ, Rubin R, Garcia-Tsao G, et al. A randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology (Baltimore, Md.). 1995;22:759-766.
8. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology. 1996;110:1515-1518.
9. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884-890.
10. Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. The Cochrane database of systematic reviews. 2008:CD000551.
11. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. The Cochrane database of systematic reviews. 2012;12:CD000551.
12. Ikeda T, Tozuka S, Noguchi O, Kobayashi F, Sakamoto S, Marumo F, Sato C. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis:a prospective randomized study. Journal of hepatology. 1996;24:88-94.
13. Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Hepatology (Baltimore, Md.). 1996;24:1098-1103.
14. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (Baltimore, Md.). 1989;10:1-7.
15. Tanaka A, Harada K, Ebinuma H, Komori A, Yokokawa J, Yoshizawa K, Abe M, Miyake Y, Kikuchi K, Ohira H, Zeniya M, Yamamoto K, Ishibashi H, et al. Primary biliary cirrhosis-Autoimmune hepatitis overlap syndrome: A rationale for corticosteroids use based on a nationwide retrospective study in Japan. Hepatology research :the official journal of the Japan Society of Hepatology. 2011;41:877-886.
16. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006;24:1-19.
17. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions:empirical evidence from published metaanalyses. BMJ. 2003;326:472.
18. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008;26:753-767.
19. Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM, Rossi SS, Hofmann AF, Baldus WP. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology (Baltimore, Md.). 1995;22:1158-1162.
20. Vuoristo M, Farkkila M, Karvonen AL, Leino R, Lehtola J, Makinen J, Mattila J, Friman C, Seppala K, Tuominen J, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 1995;108:1470-1478.
21. Leuschner U, Fischer H, Hubner K. [Ursodeoxycholic acid in the treatment of primary biliary cirrhosis:results of a controlled study]. Zeitschrift fur Gastroenterologie. Verhandlungsband. 1989;24:133.
22. Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, Tsuji T, Hattori N, Namihisa T, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterologia Japonica. 1990;25:774-780.
23. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. The New England journal of medicine. 1991;324:1548-1554.
24. Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, Pagliaro L, Manenti F. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. Journal of hepatology. 1993;17:332-338.
25. Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis:a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. Journal of gastroenterology and hepatology. 1993;8:217-223.
26. Zhu GQ, Shi KQ, You J, Zou H, Lin YQ, Wang LR, Braddock M, Chen YP, Zheng MH. Systematic review with network meta-analysis:adjuvant therapy for resected biliary tract cancer. Alimentary pharmacology & therapeutics. 2014;40:759-770.
27. Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Ryden BO, Einarsson K, Lindgren S, Wallerstedt S, Weden M. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, doubleblind, randomized controlled study. Scandinavian journal of gastroenterology. 1997;32:179-186.
28. Gonzalez-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. Journal of hepatology. 1997;27:143-149.
29. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosisautoimmune hepatitis overlap syndrome:clinical features and response to therapy. Hepatology (Baltimore, Md.). 1998;28:296-301.
30. Zhu GQ, You J, Shi KQ, He SY, Wang LR, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis:adjuvant chemotherapy for resected colorectal liver metastases. Medicine. 2015;94:e379.
31. Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Alimentary pharmacology & therapeutics. 2000;14:1645-1652.
32. Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, Berenguer J, Rodriguez-Martinez D, Mercader J, Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis:results of a double-blind controlled multicentric trial. UDCACooperative Group from the Spanish Association for the Study of the Liver. Journal of hepatology. 2000;32:561-566.
33. Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C, Villa E, Podda M. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis:a double-blind, placebocontrolled trial on symptomatic patients. Alimentary pharmacology & therapeutics. 2001;15:1427-1434.
34. Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ. Ursodeoxycholic acid for primary biliary cirrhosis:final results of a 12-year, prospective, randomized, controlled trial. The American journal of gastroenterology. 2002;97:2063-2070.
35. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment:a new medical approach for PBC patients? Journal of gastroenterology. 2003;38:573-578.
36. Ozaslan E, Efe C, Akbulut S, Purnak T, Savas B, Erden E, Altiparmak E. Therapy response and outcome of overlap syndromes:autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. Hepato-gastroenterology. 2010;57:441-446.
37. Leung J, Bonis PA, Kaplan MM. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clinical gastroenterology and hepatology :the official clinical practice journal of the American Gastroenterological Association. 2011;9:776-780.
38. Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL, Jr., et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (Baltimore, Md.). 2005;42:1184-1193.
39. Zhu GQ, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis:the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Alimentary pharmacology & therapeutics. 2015;41:624-635.
40. Bodenheimer H, Jr., Schaffner F, Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology. 1988;95:124-129.
41. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology. 1985;89:1084-1091.
42. Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, Ludwig J, McCall JT. Trial of penicillamine in advanced primary biliary cirrhosis. The New England journal of medicine. 1985;312:1011-1015.
43. Epstein O, Jain S, Lee RG, Cook DG, Boss AM, Scheuer PJ, Sherlock S. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet. 1981;1:1275-1277.
44. Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology. 1976;70:656-660.
45. Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D. Low-dose methotrexate is ineffective in primary biliary cirrhosis:long-term results of a placebo-controlled trial. Gastroenterology. 1999;117:400-407.
46. Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA. A prospective trial of colchicine for primary biliary cirrhosis. The New England journal of medicine. 1986;315:1448-1454.
47. Lombard M, Portmann B, Neuberger J, Williams R, Tygstrup N, Ranek L, Ring-Larsen H, Rodes J, Navasa M, Trepo C, et al. Cyclosporin A treatment in primary biliary cirrhosis:results of a long-term placebo controlled trial. Gastroenterology. 1993;104:519-526.
48. Matloff DS, Alpert E, Resnick RH, Kaplan MM. A prospective trial of D-penicillamine in primary biliary cirrhosis. The New England journal of medicine. 1982;306:319-326.
49. Minuk GY, Bohme CE, Burgess E, Hershfield NB, Kelly JK, Shaffer EA, Sutherland LR, Van Rosendaal G. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Gastroenterology. 1988;95:1356-1363.
50. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. Journal of hepatology. 1992;15:336-344.
51. Neuberger J, Christensen E, Portmann B, Caballeria J, Rodes J, Ranek L, Tygstrup N, Williams R. Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut. 1985;26:114-119.
52. Taal BG, Schalm SW, Ten Kate FW, Van Berge Henegouwen GP, Brandt KH. Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis. Liver. 1983;3:345-352.
53. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. Journal of hepatology. 1987;5:1-7.
54. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, Dickson ER. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. The New England journal of medicine. 1990;322:1419-1424.
55. Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology (Baltimore, Md.). 1991;14:990-993.
56. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons:Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Statistics in medicine. 2009;28:1861-1881.
57. Caldwell DM, Welton NJ, Ades AE. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. Journal of clinical epidemiology. 2010;63:875-882.
58. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC medical research methodology. 2007;7:5.
59. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver D. Primary biliary cirrhosis. Hepatology (Baltimore, Md.). 2009;50:291-308.
60. Zhang Y, Lu J, Dai W, Wang F, Shen M, Yang J, Zhu R, Zhang H, Chen K, Cheng P, He L, Wang C, Xu L, et al. Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis:a meta-analysis. Gastroenterology research and practice. 2013;2013:490731.
61. Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Journal of hepatology. 2006;44:400-406.
62. Heurgue A, Vitry F, Diebold MD, Yaziji N, BernardChabert B, Pennaforte JL, Picot R, Louvet H, Fremond L, Geoffroy P, Schmit JL, Cadiot G, Thiefin G. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis:a retrospective study of 115 cases of autoimmune liver disease. Gastroenterologie clinique et biologique. 2007;31:17-25.
63. Giljaca V, Poropat G, Stimac D, Gluud C. Methotrexate for primary biliary cirrhosis. The Cochrane database of systematic reviews. 2010:CD004385.
64. Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. The Cochrane database of systematic reviews. 2007:CD006000.
65. Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. The Cochrane database of systematic reviews. 2007:CD005526.
66. Gong Y, Frederiksen SL, Gluud C. D-penicillamine for primary biliary cirrhosis. The Cochrane database of systematic reviews. 2004:CD004789.
67. Gong Y, Klingenberg SL, Gluud C. Systematic review and meta-analysis:D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis-Cochrane Hepato-Biliary Group. Alimentary pharmacology & therapeutics. 2006;24:1535-1544.
68. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International journal of surgery (London, England). 2010;8:336-341.
69. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
70. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the metaanalysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.
71. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices:part 1. Value Health. 2011;14:417-428.
72. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in medicine. 2002;21:2313-2324.
73. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants:a multiple-treatments meta-analysis. Lancet. 2009;373:746-758.